학술논문
Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations ( NPM1, FLT3or CEBPA) Identify a High-Risk CMML Group Independent of Molecular-Cpss
Document Type
Article
Author
Castaño-Díez, Sandra; Zugasti, Ines; Calvo, Xavier; Schulz, Felicitas; Avendaño Pita, Alejandro; Mora, Elvira; Falantes, Jose Francisco; Azaceta, Gemma; Ibáñez, Mariam; Chen, Tzu; Notario, Cristina; Amer Salas, Neus; López-Guerra, Mònica; Jimenez-Vicente, Carlos; Esteban, Daniel; Guijarro, Francesca; Álamo Moreno, José Ramón; Cortés-Bullich, Albert; Munárriz, Daniel; Torrecillas-Mayayo, Víctor; Triguero, Ana; Tovar, Natalia; Martínez-Roca, Alexandra; Merchán Muñoz, Beatriz; Carcelero, Esther; Germing, Ulrich; Betz, Beate; Rozman, María; Arenillas, Leonor; Zamora, Lurdes; Diez-Campelo, Maria; Xicoy, Blanca; Esteve, Jordi; Díaz-Beyá, Marina
Source
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p3231-3231, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
CMML is rarely associated with AML typical mutations such as NPM1, FLT3, CEBPAand IDH1/2 (mutAML-CMML). It is unknown what its clinical meaning is and if its presence should change our management into an AML-type treatment. The aim was to describe the characteristics, prognosis and treatment of mutAML-CMML patients.